Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

Yongchao Wang, Warren Fiskus, Daniel G. Chong, Kathleen M. Buckley, Kavita Natrajan, Rekha Rao, Atul Joshi, Ramesh Balusu, Sanjay Koul, Jianguang Chen, Andrew Savoie, Celalettin Ustun, Anand Jillella, Peter Atadja, Ross L. Levine, Kapil N. Bhalla

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs). JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 (PI3)/AKT pathways, conferring proliferative and survival advantages in the MPN hematopoietic progenitor cells (HPCs). Treatment with the pan-histone deacetylase (HDAC) inhibitor panobinostat (PS) is known to inhibit the chaperone function of heat shock protein 90, as well as induce growth arrest and apoptosis of transformed HPCs. Here, we demonstrate that PS treatment depletes the autophosphorylation, expression, and downstream signaling of JAK2V617F. Treatment with PS also disrupted the chaperone association of JAK2V617F with hsp90, promoting proteasomal degradation of JAK2V617F. PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells. Treatment with the JAK2 TK inhibitor TG101209 attenuated JAK2V617F autophosphorylation and induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells. Cotreatment with PS and TG101209 further depleted JAK/STAT signaling and synergistically induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells. Cotreatment with TG101209 and PS exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34 + HPCs. These in vitro findings suggest combination therapy with HDAC and JAK2V617F inhibitors is of potential value for the treatment of JAK2V617F-positive MPN.

Original languageEnglish (US)
Pages (from-to)5024-5033
Number of pages10
JournalBlood
Volume114
Issue number24
DOIs
StatePublished - Dec 3 2009

Fingerprint

Hematopoietic Stem Cells
Apoptosis
Histone Deacetylase Inhibitors
Transcription
Transducers
Protein-Tyrosine Kinases
Neoplasms
Therapeutics
HSP90 Heat-Shock Proteins
Leukemia, Erythroblastic, Acute
Mitogen-Activated Protein Kinase 3
Cytotoxicity
Phosphatidylinositols
Mitogen-Activated Protein Kinases
TG101209
panobinostat
Association reactions
Degradation
Survival
Growth

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. / Wang, Yongchao; Fiskus, Warren; Chong, Daniel G.; Buckley, Kathleen M.; Natrajan, Kavita; Rao, Rekha; Joshi, Atul; Balusu, Ramesh; Koul, Sanjay; Chen, Jianguang; Savoie, Andrew; Ustun, Celalettin; Jillella, Anand; Atadja, Peter; Levine, Ross L.; Bhalla, Kapil N.

In: Blood, Vol. 114, No. 24, 03.12.2009, p. 5024-5033.

Research output: Contribution to journalArticle

Wang, Y, Fiskus, W, Chong, DG, Buckley, KM, Natrajan, K, Rao, R, Joshi, A, Balusu, R, Koul, S, Chen, J, Savoie, A, Ustun, C, Jillella, A, Atadja, P, Levine, RL & Bhalla, KN 2009, 'Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells', Blood, vol. 114, no. 24, pp. 5024-5033. https://doi.org/10.1182/blood-2009-05-222133
Wang, Yongchao ; Fiskus, Warren ; Chong, Daniel G. ; Buckley, Kathleen M. ; Natrajan, Kavita ; Rao, Rekha ; Joshi, Atul ; Balusu, Ramesh ; Koul, Sanjay ; Chen, Jianguang ; Savoie, Andrew ; Ustun, Celalettin ; Jillella, Anand ; Atadja, Peter ; Levine, Ross L. ; Bhalla, Kapil N. / Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. In: Blood. 2009 ; Vol. 114, No. 24. pp. 5024-5033.
@article{92dcf1f36457482f9c34fe06f204bcaf,
title = "Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells",
abstract = "The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs). JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 (PI3)/AKT pathways, conferring proliferative and survival advantages in the MPN hematopoietic progenitor cells (HPCs). Treatment with the pan-histone deacetylase (HDAC) inhibitor panobinostat (PS) is known to inhibit the chaperone function of heat shock protein 90, as well as induce growth arrest and apoptosis of transformed HPCs. Here, we demonstrate that PS treatment depletes the autophosphorylation, expression, and downstream signaling of JAK2V617F. Treatment with PS also disrupted the chaperone association of JAK2V617F with hsp90, promoting proteasomal degradation of JAK2V617F. PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells. Treatment with the JAK2 TK inhibitor TG101209 attenuated JAK2V617F autophosphorylation and induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells. Cotreatment with PS and TG101209 further depleted JAK/STAT signaling and synergistically induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells. Cotreatment with TG101209 and PS exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34 + HPCs. These in vitro findings suggest combination therapy with HDAC and JAK2V617F inhibitors is of potential value for the treatment of JAK2V617F-positive MPN.",
author = "Yongchao Wang and Warren Fiskus and Chong, {Daniel G.} and Buckley, {Kathleen M.} and Kavita Natrajan and Rekha Rao and Atul Joshi and Ramesh Balusu and Sanjay Koul and Jianguang Chen and Andrew Savoie and Celalettin Ustun and Anand Jillella and Peter Atadja and Levine, {Ross L.} and Bhalla, {Kapil N.}",
year = "2009",
month = "12",
day = "3",
doi = "10.1182/blood-2009-05-222133",
language = "English (US)",
volume = "114",
pages = "5024--5033",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

AU - Wang, Yongchao

AU - Fiskus, Warren

AU - Chong, Daniel G.

AU - Buckley, Kathleen M.

AU - Natrajan, Kavita

AU - Rao, Rekha

AU - Joshi, Atul

AU - Balusu, Ramesh

AU - Koul, Sanjay

AU - Chen, Jianguang

AU - Savoie, Andrew

AU - Ustun, Celalettin

AU - Jillella, Anand

AU - Atadja, Peter

AU - Levine, Ross L.

AU - Bhalla, Kapil N.

PY - 2009/12/3

Y1 - 2009/12/3

N2 - The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs). JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 (PI3)/AKT pathways, conferring proliferative and survival advantages in the MPN hematopoietic progenitor cells (HPCs). Treatment with the pan-histone deacetylase (HDAC) inhibitor panobinostat (PS) is known to inhibit the chaperone function of heat shock protein 90, as well as induce growth arrest and apoptosis of transformed HPCs. Here, we demonstrate that PS treatment depletes the autophosphorylation, expression, and downstream signaling of JAK2V617F. Treatment with PS also disrupted the chaperone association of JAK2V617F with hsp90, promoting proteasomal degradation of JAK2V617F. PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells. Treatment with the JAK2 TK inhibitor TG101209 attenuated JAK2V617F autophosphorylation and induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells. Cotreatment with PS and TG101209 further depleted JAK/STAT signaling and synergistically induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells. Cotreatment with TG101209 and PS exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34 + HPCs. These in vitro findings suggest combination therapy with HDAC and JAK2V617F inhibitors is of potential value for the treatment of JAK2V617F-positive MPN.

AB - The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs). JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 (PI3)/AKT pathways, conferring proliferative and survival advantages in the MPN hematopoietic progenitor cells (HPCs). Treatment with the pan-histone deacetylase (HDAC) inhibitor panobinostat (PS) is known to inhibit the chaperone function of heat shock protein 90, as well as induce growth arrest and apoptosis of transformed HPCs. Here, we demonstrate that PS treatment depletes the autophosphorylation, expression, and downstream signaling of JAK2V617F. Treatment with PS also disrupted the chaperone association of JAK2V617F with hsp90, promoting proteasomal degradation of JAK2V617F. PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells. Treatment with the JAK2 TK inhibitor TG101209 attenuated JAK2V617F autophosphorylation and induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells. Cotreatment with PS and TG101209 further depleted JAK/STAT signaling and synergistically induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells. Cotreatment with TG101209 and PS exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34 + HPCs. These in vitro findings suggest combination therapy with HDAC and JAK2V617F inhibitors is of potential value for the treatment of JAK2V617F-positive MPN.

UR - http://www.scopus.com/inward/record.url?scp=73949136283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949136283&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-05-222133

DO - 10.1182/blood-2009-05-222133

M3 - Article

VL - 114

SP - 5024

EP - 5033

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -